for the Period Ended 31 May 2021
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 May 2021
Principal activities of the company
Directors
The director shown below has held office during the whole of the period from
1 June 2020 to 31 May 2021
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
2021 | 8 months to 31 May 2020 | |
---|---|---|
| £ | £ |
Turnover: | | |
Cost of sales: | ( | ( |
Gross profit(or loss): | | |
Administrative expenses: | ( | ( |
Operating profit(or loss): | | |
Profit(or loss) before tax: | | |
Tax: | ( | ( |
Profit(or loss) for the financial year: | | |
As at
Notes | 2021 | 8 months to 31 May 2020 | |
---|---|---|---|
| £ | £ | |
Current assets | |||
Debtors: | 3 | | |
Cash at bank and in hand: | | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 4 | ( | ( |
Net current assets (liabilities): | | | |
Total assets less current liabilities: | | | |
Total net assets (liabilities): | | | |
Capital and reserves | |||
Called up share capital: | | | |
Profit and loss account: | | | |
Total Shareholders' funds: | | |
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 May 2021
Basis of measurement and preparation
Turnover policy
Intangible fixed assets amortisation policy
for the Period Ended 31 May 2021
2021 | 8 months to 31 May 2020 | |
---|---|---|
Average number of employees during the period | | |
for the Period Ended 31 May 2021
2021 | 8 months to 31 May 2020 | |
---|---|---|
£ | £ | |
Trade debtors | | |
Total | | |
for the Period Ended 31 May 2021
2021 | 8 months to 31 May 2020 | |
---|---|---|
£ | £ | |
Taxation and social security | | |
Other creditors | | |
Total | | |
Throughout the previous year, the Covid-19 pandemic had a significant effect on the normal business activities of a great number of Orion Medtech’s NHS and academic stakeholders. Despite these challenges, the company has met its objectives to promote high quality healthcare in the UK during the financial year ending 31 May 2021 through the following activities:Orion MedTech supported academic research in the field of medicine by providing a data collection platform and analysing anonymised clinical data for a study funded by the National Institute of Health Research (NIHR). The Global Health Research Group on Neurotrauma developed a multi-centre, international, prospective cohort study of patients undergoing emergency surgery for Traumatic Brain Injury. The 180 study sites included most UK NHS major trauma Trusts as well as hospitals in lower and middle income countries. Academic and technical support was provided at no cost. Further academic and technical support was provided for the development of a registry to map the pre-hospital, acute in-hospital, and post-acute care of patients suffering Traumatic Brain Injury. The registry was first launched in August 2020 at Addenbrooke’s hospital in Cambridge, UK for service evaluation, following which it was made available worldwide and received endorsement from the World Federation of Neurosurgical Societies (WFNS).In June 2020 Orion MedTech began a collaboration with leading clinical researchers in the field of Parkinson’s disease, Neuropsychiatry and Neurosurgery in the UK. The collaboration was to develop a multi-centre, observational study of impulsive behaviours following Deep Brain Stimulation (DBS) in Parkinson's Disease. The study aims to exploit the rich data collected in the national DBS registry hosted by Orion MedTech and will further develop our understanding of the condition and its response to DBS surgery. The study has received IRAS approval and is awaiting local site approvals. The collaboration contribution by Orion MedTech has been provided without charge.In May 2021 Orion MedTech began work with a small company developing a pioneering state-of-the-art technology that accurately differentiates tumour from non-tumour during surgery using computer vision. Orion MedTech provided project management and grant application support without cost to assist the company is acquiring funding for further development and commercialisation of the solution. In February 2021, Orion MedTech appointed a Chief Operations Officer as its first in-house employee. The appointment brought in to the organisation substantial NHS operational experience, as well as increased resource and capacity to broaden activities.The pandemic affected the capability of NHS Trusts to contribute to national registries that are hosted by Orion MedTech. Therefore benchmarking and quality assurance reports were significantly scaled down so as not to increase the pressure on overloaded staff and clinicians. Nonetheless, a total of 38 reports were published to 30 NHS Trusts, which can be used to identify service improvement opportunities and best practice, for the benefit of the specialist services provided by the recipient NHS Trusts. These services include neurovascular treatment and medical implant services to treat hydrocephalus.Orion MedTech continues to work with the Medicines and Healthcare products Regulatory Agency and manufacturers of medical implants to provide a data analysis service which allows post-market surveillance of medical devices and identification of adverse events related to implanted devices in UK patients.Orion MedTech continues to provide software solutions and support to 38 NHS Trusts, many of which are made available without charge, or at cost.
No consultation with stakeholders
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
22 February 2022
And signed on behalf of the board by:
Name: Alexis JOANNIDES
Status: Director